
    
      CD123 is a transmembrane subunit of the IL-3 receptor expressed on AML blasts. The
      investigators have conducted a third generationCD123-targeted CAR containing CD137 and CD28
      costimulatory domains.This study aims to evaluate the safety and efficacy of anti-CD123 CAR-T
      cells in patients with relapsed/refractory CD123+ Acute Myeloid Leukemia.
    
  